<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/29701399-82AA-477C-8B54-1EC05F187870"><gtr:id>29701399-82AA-477C-8B54-1EC05F187870</gtr:id><gtr:firstName>Sean</gtr:firstName><gtr:otherNames>Hua</gtr:otherNames><gtr:surname>Lim</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800457"><gtr:id>D0794471-ACB7-4E51-BFE5-48016D30BF5A</gtr:id><gtr:title>The role of Fc gamma receptors in regulating the response to antibody therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800457</gtr:grantReference><gtr:abstractText>Many therapeutic antibodies work by binding to Fc gamma Receptors- found on immune effector cells. It is not clear whether the effector cells are instrumental in killing the target cells, or whether they simply provide a means to cross-link the antibody molecules, and thereby deliver lethal signals into them. This project aims to determine which of these is more important, and to decipher which immune cells are involved. If we understand this process we can seek to improve current antibody therapies to make them more efficacious or less toxic</gtr:abstractText><gtr:technicalSummary>In the last decade, the CD20 antibody Rituximab has transformed the treatment of B-cell lymphoma. It is possible that it may have a similar effect in the treatment of autoimmune disorders such as rheumatoid arthritis and SLE. Current evidence shows that its effects are critically dependent upon activating Fc gamma receptors (Fc R). Conventionally, this dependency has been attributed to direct tumour killing by effector cells which become activated through their Fc R after Rituximab engagement. If this were the dominant mechanism, then antibodies to other highly-expressed antigens such as CD19 should be equally potent, which they are not. Therefore, we suggest that an additional critical component of the anti-tumour effect of Rituximab derives from its ability to transmit signals into the target cell. We recently showed that two of these signals (calcium flux and ERK1/2 activation) occur after Rituximab binding only when additional cross-linking is provided. Furthermore, we also found that both of these signals are critically dependent upon expression of the B-cell receptor (BCR). Based upon these data, we propose that effective CD20 immunotherapy is due to enhanced signalling in the target cells as a result of Fc R-dependent hyper-crosslinking. 

The aims of this project are to study CD20 antibody signalling, its dependency on BCR expression and how this is enhanced by Fc R-expressing effector cells. Furthermore, we hypothesise that higher affinity Fc R allotypes provide increased signalling and will use a range of antibodies, cell lines and primary cells expressing different levels of BCR to investigate this further. We will assess signalling in the cells by measuring calcium flux and ERK1/2 activation after coating the target cells with anti-CD20 mAb. Crosslinking of the mAb will be afforded by secondary antibodies, effector cells or Fc R fusion proteins. Calcium flux will be assessed using flow cytometry and confocal microscopy. ERK1/2 activation will be studied using phospho-specific reagents in Western blotting and flow cytometry. 

This work builds upon our previous studies and will provide a clearer understanding of how antibodies signal in primary normal and malignant B cells, thereby pointing to how these reagents might be augmented and better applied in the next generation of antibodies which is now entering clinical trials. The knowledge gained could make a major contribution to the subsequent treatment of patients with autoimmunity and cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>188331</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Leukaemia and Lymphoma Research Press Releases</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>AB09CC4C-9CF1-4727-8B4B-91ADA18563A5</gtr:id><gtr:impact>Press releases were issued by co-sponsor Leukaemia and Lymphoma Research when our research was newly published.

The press releases led to further releases of the first research article in New Boundaries magazine and the local paper, Daily Echo. The second research article was presented on the radio station Jack FM.</gtr:impact><gtr:outcomeId>AraFmWLw5fY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Leukaemia and Lymphoma Research Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>DECD691E-EDBD-45D1-AF4F-FD1A8022EDC4</gtr:id><gtr:impact>The research was presented at the Leukaemia and Lymphoma Research Open today to an audience of over 100 people.

Much interest was raised in the audience.</gtr:impact><gtr:outcomeId>M4MKMc7rqYG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>70CAF056-4D4A-4048-9E92-C00D99C9E9F2</gtr:id><gtr:title>Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/766a0b0829fda850fb166d79320ded3c"><gtr:id>766a0b0829fda850fb166d79320ded3c</gtr:id><gtr:otherNames>Lim SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>eJkz6nhd1bU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73B65DD6-23F9-4802-859C-ABC7F0E4504E</gtr:id><gtr:title>Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22663b2a5c4ac861757701ee94a285b9"><gtr:id>22663b2a5c4ac861757701ee94a285b9</gtr:id><gtr:otherNames>Beers SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>dKgZKhHPQ21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E772B1BD-1DC4-432C-B67F-5A841DEE33D0</gtr:id><gtr:title>Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/133b01446fa83b3df139a68b41ca7d58"><gtr:id>133b01446fa83b3df139a68b41ca7d58</gtr:id><gtr:otherNames>Alduaij W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>TPznCZBA9KB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD7F8611-4FE6-46C4-8D5D-5642A4E98DAC</gtr:id><gtr:title>Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fc? Receptors.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab93fc144d04db92c4183d554aeb15f"><gtr:id>4ab93fc144d04db92c4183d554aeb15f</gtr:id><gtr:otherNames>Tutt AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56cd7fac477046.82941965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C4B939B-A01B-4F1D-81E7-22814BCB92DB</gtr:id><gtr:title>Inhibitory Fc?RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/661d7a45fb8f265499a10d5897238e5a"><gtr:id>661d7a45fb8f265499a10d5897238e5a</gtr:id><gtr:otherNames>Vaughan AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>544881b95e0a68.14411317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCC4F83D-B4A9-456F-A714-B1FADCC05FAA</gtr:id><gtr:title>Anti-CD20 monoclonal antibodies: historical and future perspectives.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/766a0b0829fda850fb166d79320ded3c"><gtr:id>766a0b0829fda850fb166d79320ded3c</gtr:id><gtr:otherNames>Lim SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>D9B57A37ECC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C5A6812-C0F0-4D20-AA5D-2E907948EA5A</gtr:id><gtr:title>Chemotherapy: Advanced Hodgkin lymphoma--balancing toxicity and cure.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/766a0b0829fda850fb166d79320ded3c"><gtr:id>766a0b0829fda850fb166d79320ded3c</gtr:id><gtr:otherNames>Lim SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>keUt3PfiSt1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B8B8AF1-8B95-4A48-9F21-EA292DE785F9</gtr:id><gtr:title>Tumours of the Immune System</gtr:title><gtr:parentPublicationTitle>Encyclopedia of Life Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8d611208d3ef55a60cfe07008688b95"><gtr:id>f8d611208d3ef55a60cfe07008688b95</gtr:id><gtr:otherNames>Johnson Peter</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>M5jTvymH84R</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800457</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>